{"id":414713,"date":"2021-01-14T07:03:58","date_gmt":"2021-01-14T12:03:58","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=414713"},"modified":"2021-01-14T07:03:58","modified_gmt":"2021-01-14T12:03:58","slug":"bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/","title":{"rendered":"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium"},"content":{"rendered":"

<\/p>\n

BELLUS Health to Present at the Eleventh International Virtual Cough Symposium<\/b><\/p>\n

LAVAL, Quebec–(BUSINESS WIRE<\/a>)–
\nBELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (\u201cBELLUS Health\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health’s Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health\u2019s Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the Eleventh International Virtual Cough Symposium being held on January 21-22, 2021.\n<\/p>\n

Oral Presentations:<\/b><\/p>\n

Title: <\/b>Results of RELIEF, a Phase 2a study with BLU-5937 in Refractory Chronic Cough
\n
Details:<\/b> The presentation will highlight nominal effect size and baseline characteristics of the ITT population in the RELIEF trial, as well as for two pre-specified sub-groups (\u226520 coughs per hour at baseline and \u226532 coughs per hour at baseline).
\n
Session: <\/b>Clinical trials of antitussive therapies
\n
Date: <\/b>Friday, January 22
\n
Time: <\/b>1:00 \u2013 3:30 p.m. GMT \/ 8:00 \u2013 10:30 a.m. EST\n<\/p>\n

Title: <\/b>BLU-5937, A Potent and Selective P2X3 Receptor Antagonist, Presents a Promising New Approach for the Treatment of Chronic Pruritus in Atopic Dermatitis Patients
\n
Details:<\/b> The presentation will highlight preclinical data that support the potential efficacy of P2X3 antagonists in the treatment of atopic dermatitis-derived pruritus.
\n
Session: <\/b>Migraine, itch and chronic cough (Q&A session)
\n
Date: <\/b>Friday, January 22
\n
Time:<\/b> 3:45 \u2013 5:00 p.m. GMT \/ 10:45 \u2013 12:00 p.m. EST<\/p>\n

\nFollowing the conference, the presentations will be available in the \u201cScientific Publications\u201d section of BELLUS Health’s website at www.bellushealth.com<\/a>.\n<\/p>\n

\n

About BELLUS Health (<\/b>www.bellushealth.com<\/a>)<\/b><\/p>\n

\nBELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus.\n<\/p>\n

\nChronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with approximately 3 million having refractory chronic cough lasting for more than a year and approximately 6 million having refractory chronic cough lasting more than 8 weeks and under one year. There is no specific therapy approved for refractory chronic cough and current treatment options are limited.\n<\/p>\n

\nChronic pruritus, commonly known as chronic itch, is an irritating sensation that leads to scratching, and persists for longer than six weeks, which can be debilitating and has a significant impact on quality-of-life. It is a hallmark of many dermatologic disorders, including atopic dermatitis (AD). It is estimated that chronic pruritus associated with AD affects more than 16.9 million adults in the United States.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210114005220\/en\/<\/a><\/span><\/p>\n

\nDanny Matthews
\n
Director, Investor Relations and Communications
\n
danny@bellushealth.com<\/a><\/p>\n

Media:
\n<\/b>
Julia Deutsch
\n
Solebury Trout
\n
jdeutsch@soleburytrout.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

BELLUS Health to Present at the Eleventh International Virtual Cough Symposium LAVAL, Quebec–(BUSINESS WIRE)– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (\u201cBELLUS Health\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health’s Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health\u2019s Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the Eleventh International Virtual Cough Symposium being held on January 21-22, 2021. Oral Presentations: Title: Results of RELIEF, a Phase 2a study with BLU-5937 in Refractory Chronic Cough Details: The presentation will highlight nominal effect size and baseline characteristics of the ITT population in the RELIEF … <\/p>\n

Continue reading “BELLUS Health to Present at the Eleventh International Virtual Cough Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-414713","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBELLUS Health to Present at the Eleventh International Virtual Cough Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium LAVAL, Quebec–(BUSINESS WIRE)– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (\u201cBELLUS Health\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health’s Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health\u2019s Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the Eleventh International Virtual Cough Symposium being held on January 21-22, 2021. Oral Presentations: Title: Results of RELIEF, a Phase 2a study with BLU-5937 in Refractory Chronic Cough Details: The presentation will highlight nominal effect size and baseline characteristics of the ITT population in the RELIEF … Continue reading "BELLUS Health to Present at the Eleventh International Virtual Cough Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-14T12:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium\",\"datePublished\":\"2021-01-14T12:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/\"},\"wordCount\":508,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/\",\"name\":\"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-14T12:03:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/","og_locale":"en_US","og_type":"article","og_title":"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium - Market Newsdesk","og_description":"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium LAVAL, Quebec–(BUSINESS WIRE)– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (\u201cBELLUS Health\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health’s Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health\u2019s Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the Eleventh International Virtual Cough Symposium being held on January 21-22, 2021. Oral Presentations: Title: Results of RELIEF, a Phase 2a study with BLU-5937 in Refractory Chronic Cough Details: The presentation will highlight nominal effect size and baseline characteristics of the ITT population in the RELIEF … Continue reading \"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-14T12:03:58+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium","datePublished":"2021-01-14T12:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/"},"wordCount":508,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/","name":"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-14T12:03:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210114005220r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bellus-health-to-present-at-the-eleventh-international-virtual-cough-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BELLUS Health to Present at the Eleventh International Virtual Cough Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=414713"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414713\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=414713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=414713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=414713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}